162 related articles for article (PubMed ID: 33966647)
1. Opportunities and Challenges in Translational Research: The Development of Photodynamic Therapy and Anti-Vascular Endothelial Growth Factor Drugs.
Marko CK; Miller JW
J Law Med Ethics; 2021; 49(1):19-24. PubMed ID: 33966647
[TBL] [Abstract][Full Text] [Related]
2. [The revolution in the treatment of retinal diseases: anti-VEGF treatment at the Assuta Eye Institute].
Katz G; Zehavi C; Treister G
Harefuah; 2015 Apr; 154(4):270-3, 278. PubMed ID: 26065226
[TBL] [Abstract][Full Text] [Related]
3. Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development.
Hanout M; Ferraz D; Ansari M; Maqsood N; Kherani S; Sepah YJ; Rajagopalan N; Ibrahim M; Do DV; Nguyen QD
Biomed Res Int; 2013; 2013():830837. PubMed ID: 24319688
[TBL] [Abstract][Full Text] [Related]
4. [Prospects and Challenges of Anti-VEGF Drug Treatment for Pathological Angiogenesis of the Retina].
Nakamura S; Hara H
Yakugaku Zasshi; 2021; 141(12):1307-1317. PubMed ID: 34853203
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and current treatment of age-related macular degeneration.
Yonekawa Y; Kim IK
Cold Spring Harb Perspect Med; 2014 Oct; 5(1):a017178. PubMed ID: 25280900
[TBL] [Abstract][Full Text] [Related]
6. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
Chong V
Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity.
VanderVeen DK; Cataltepe SU
Semin Perinatol; 2019 Oct; 43(6):375-380. PubMed ID: 31174872
[TBL] [Abstract][Full Text] [Related]
8. Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.
Yazdi MH; Faramarzi MA; Nikfar S; Falavarjani KG; Abdollahi M
Expert Opin Biol Ther; 2015; 15(9):1349-58. PubMed ID: 26076760
[TBL] [Abstract][Full Text] [Related]
9. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
de Oliveira Dias JR; Rodrigues EB; Maia M; Magalhães O; Penha FM; Farah ME
Br J Ophthalmol; 2011 Dec; 95(12):1631-7. PubMed ID: 21546514
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
11. Neovascular age-related macular degeneration.
Veritti D; Sarao V; Lanzetta P
Ophthalmologica; 2012; 227 Suppl 1():11-20. PubMed ID: 22517121
[TBL] [Abstract][Full Text] [Related]
12. Unexpected hypotony after glaucoma drainage implant surgery associated with anti-vascular endothelial growth factor treatment.
Hoguet A; Parrish RK
JAMA Ophthalmol; 2015 Mar; 133(3):349-50. PubMed ID: 25474585
[No Abstract] [Full Text] [Related]
13. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
Zhou S; Gao J; Xu X
Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
[TBL] [Abstract][Full Text] [Related]
14. [Review and expert opinion in age related macular degeneration. Focus on the pathophysiology, angiogenesis and pharmacological and clinical data].
Weber M; Sennlaub F; Souied E; Cohen SY; Béhar-Cohen F; Milano G; Tadayoni R
J Fr Ophtalmol; 2014 Sep; 37(7):566-79. PubMed ID: 25190312
[TBL] [Abstract][Full Text] [Related]
15. Anti-vascular endothelial growth factor for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Evans JR
Cochrane Database Syst Rev; 2014 Oct; (10):CD007419. PubMed ID: 25342124
[TBL] [Abstract][Full Text] [Related]
16. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic modalities of exudative age-related macular degeneration.
Mavija M; Alimanovic E; Jaksic V; Kasumovic SS; Cekic S; Stamenkovic M
Med Arh; 2014; 68(3):204-8. PubMed ID: 25195354
[TBL] [Abstract][Full Text] [Related]
18. Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Schachat AP
Am J Ophthalmol; 2013 Jul; 156(1):1-2.e1. PubMed ID: 23791369
[No Abstract] [Full Text] [Related]
19. [Anti-VEGF therapy to treat diabetic macular edema].
Takamura Y
Nippon Ganka Gakkai Zasshi; 2014 Sep; 118(9):747-9. PubMed ID: 25318182
[No Abstract] [Full Text] [Related]
20. Treating age-related macular degeneration - interaction of VEGF-antagonists with their target.
Klettner A; Roider J
Mini Rev Med Chem; 2009 Aug; 9(9):1127-35. PubMed ID: 19689408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
